Myomo publishes investor presentation on wearable robotics for upper-limb paralysis

Myomo, Inc.

MYO

0.00

Myomo outlined a strategy pivot toward recurring patient sources, expanded payer contracting, operating leverage, product development, and research investment.
Highlighted Medicare reimbursement support, citing a Medicare fee of USD 68,800 for the MyoPro 2x Motion G device.
Reported Q1 2026 revenue of USD 10.11 million, gross margin of 68.2%, operating loss of USD 3.16 million, net loss of USD 3.01 million.
Showed cash and investments of USD 15.7 million, debt of USD 12.57 million, shareholders’ equity of USD 9 million, shares outstanding of 42,330,000.
Reiterated a longer-term target of more than USD 100 million annual revenue, 70% gross margin, positive EBITDA, cash flow.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myomo Inc. published the original content used to generate this news brief on June 23, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.